Compare ProShares Ultra QQQ ETF (QLD) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Zoetis Inc — how do they compare? ProShares Ultra QQQ ETF trades at $89.57, while Zoetis Inc trades at $73.65 (market cap $30.29B). The key difference: Zoetis Inc pays a 2.89% dividend while ProShares Ultra QQQ ETF pays none, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| QLD | ZTS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $100.53 | $150.61 |
52-Week Low | $57.16 | $71.91 |
Market Cap | — | $30.29B |
Enterprise Value | — | $37.86B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD (ProShares Ultra QQQ ETF) trades at $90.53, down 0.17% with a bullish technical signal from moving averages. The ETF has delivered over 10,000% total return since inception, demonstrating powerful compounding. Recent institutional buying includes 180 Wealth Advisors increasing their position by 29.4% in Q2 2026. Technical indicators show strong moving average support but neutral oscillators, with key support at $88-90 and resistance at $91-93 levels.
As a daily leveraged ETF tracking the Nasdaq-100, QLD offers amplified exposure to large-cap tech but carries inherent volatility risks. The current neutral RSI and ADX suggest consolidation near support levels. Institutional accumulation and strong historical performance support long-term growth potential, though leveraged structure requires careful risk management during market turbulence.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
